ECS Botanics Holdings Ltd (ASX:ECS) Reports Strong B2C Growth
ECS Botanics reports significant growth in B2C sales and strong operational performance for Q2 FY25.
Category: Healthcare
Sprintex Limited (ASX:SIX) Reports Solid December Quarter Achievements
Sprintex Limited (ASX:SIX) reports significant sales commitments and operational gains for the December quarter, reinforcing growth prospects.
Singular Health Group Limited (ASX:SHG) Reports Strong Developments in Quarterly Activities Report
Singular Health Group (ASX: SHG) reports key partnerships, equity raise success, and a solid cash position as of December 31, 2024.
Sigma Healthcare Limited (ASX:SIG) Reports Record Sales and Margin Growth
Sigma Healthcare reports Chemist Warehouse Group’s record sales and margin growth for 1H FY25 amid robust trading performance.
IDT Australia Limited (ASX:IDT) Sees 82% Revenue Surge
IDT Australia Limited (ASX:IDT) reports an 82% revenue increase, primarily driven by growth in the Advanced Therapies business segment.
Oneview Healthcare PLC (ASX:ONE) Reports Q4 2024 Cash Flow
Oneview Healthcare PLC (ASX:ONE) reports strong financial activity and operational growth in its Q4 2024 cash flow report.
Phoslock Environmental Technologies Limited (ASX: PET) Reports December 2024 Quarterly Activities
Phoslock Environmental Technologies Limited reports financial results and operational updates for the December quarter 2024 in its latest activities report.
Alterity Therapeutics Limited (ASX:ATH) Reports Q2 FY25 Cash Flow and Clinical Updates
Alterity Therapeutics (ASX:ATH) reports Q2 FY25 financial performance, trial advancements for ATH434, and future funding outlook.
Universal Biosensors, Inc. (ASX:UBI) Quarterly Activity Report Released
Universal Biosensors, Inc. (ASX:UBI) reports increased cash outflows but maintains positive cash position of $8.9 million as it develops diverse biosensors.
Income Asset Management Group Limited (ASX:IAM) Reports Q2 FY2025 Results
Income Asset Management Group Limited (ASX:IAM) announces revenue stability, client growth, and strategic financial moves for Q2 FY2025.